The first patient has been enrolled in a phase 2b trial of topical ocular reproxalap for dry eye disease, according to a press release from Aldeyra Therapeutics.
Two concentrations of topical reproxalap, 0.1% and 0.25%, will be evaluated against vehicle over a 12-week treatment period in 300 patients with moderate dry eye disease.
Reproxalap is generated from the company’s aldehyde trap platform, and it sequesters and facilitates the degradation of pro-inflammatory aldehyde mediators, the release said.
Trial results are expected to be announced in the second half of the year.
Uncategorized